Europe must preserve the resilience and autonomy of its healthcare model in a fragmented world, according to a recent briefing published by asset management firm Candriam. Long reliant on globalized supply chains, the continent has massively outsourced production of essential health products, including basic protective equipment, anesthetics, and antibiotics.
Supply Chain Fragility and Geopolitical Pressures
The COVID-19 pandemic exposed severe risks tied to this reliance, demonstrating that basic drug access is a matter of strategic security as well as public health, according to Candriam. Compounding these supply chain vulnerabilities are geopolitical pressures, including recent initiatives from the United States administration. Specifically, a most-favored-nation pricing policy aims to align US drug prices with the lowest rates found in comparable developed markets, ignoring structural differences between health systems in the US and Europe.
Internal Structural Weaknesses Threaten Health Sovereignty
While European Union member states provide healthcare services to more than 90% of their populations, according to data from the Organisation for Economic Co-operation and Development (OECD) cited in the report, internal structural weaknesses pose an even greater threat to the continent’s health sovereignty. Budget deficits and rising populism have forced the healthcare sector to cut, delay, or ration care across the region. Furthermore, EU regulations on medical devices and in vitro diagnostic medical devices have created adaptation hurdles, certification delays, and a drop in product launches, according to industry group MedTech Europe. Persistent fragmentation among member states also continues to undermine overall competitiveness.
Legislative Push and Economic Stakes in the Pharmaceutical Sector
Between late 2025 and mid-2026, the EU experienced its most active period for health policy in a generation, taking legislative action on pharmaceutical reform, supply chain security, medical device regulation, biotechnology, and health data, according to the European Commission. A key milestone arrived in May 2026, when the European Parliament and the Council of the European Union reached a provisional political agreement on the Critical Medicines Act, as noted by the Council. This legislation aims to prevent essential drug shortages, lower third-country dependencies, and boost the competitiveness of Europe’s pharmaceutical sector. The industry directly employs over 900’000 people and generates upwards of €400 milliards in annual production, although its share of global pharmaceutical output and research and development investment has shrunk compared to the US and parts of Asia.
Investment Opportunities in European Health Autonomy
Candriam identifies several avenues for investment stemming from the EU’s push for health sovereignty. Pharmaceutical and biotechnology companies remain central due to their innovation and research capacity, as well as their role in maintaining manufacturing plants within Europe. Generics and biosimilars form another cornerstone by curbing reliance on US-sourced innovative drugs and keeping healthcare systems affordable and well-supplied. Additionally, contract development and manufacturing organizations (CDMOs) and bioprocesses allow governments to repatriate the production of active pharmaceutical ingredients and diversify away from Asian suppliers.
Frequently Asked Questions
Why is Europe seeking greater health autonomy?
The pandemic exposed severe vulnerabilities in globalized supply chains for essential medicines and protective gear, prompting the EU to treat basic drug access as a matter of strategic security.
What was the Critical Medicines Act agreement?
Reached in May 2026 between the European Parliament and the Council of the EU, the provisional agreement targets essential drug shortages, aims to reduce third-country reliance, and supports the competitiveness of Europe’s pharmaceutical industry.
What sectors are central to European health sovereignty investments?
Key areas include pharmaceuticals and biotechnology, generics and biosimilars, and contract development and manufacturing organizations (CDMOs) that enable localized production of active pharmaceutical ingredients.